GlassScriptPhysician profile
Jan Smogorzewski
NPI 1710366760
$41,033.60
in general payments reported to CMS, 2019-2025
14 companies · $30K in 2025
The $30K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $140 · 2021: $149 · 2022: $156 · 2023: $2,115 · 2024: $8,332 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $15K · Travel and Lodging: $3,689 · Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,880.00 |
| Consulting Fee | $15,105.00 |
| Travel and Lodging | $3,688.76 |
| Food and Beverage | $1,475.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $22,964.94 | 2023-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $17,165.20 | 2019-2025 | |
| Abbvie INC. | $293.66 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.97 | 2022 | |
| Celgene Corporation | $124.83 | 2019 | |
| Smith+Nephew, INC. | $101.57 | 2023 | Collagenase Santyl |
| Regeneron Healthcare Solutions, INC. | $36.00 | 2020 | |
| Lilly USA, LLC | $24.24 | 2021 | |
| Janssen Biotech, INC. | $20.13 | 2020 | |
| Genzyme Corporation | $20.00 | 2020 | |
| Stemline Therapeutics INC. | $16.86 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.20 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Smogorzewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.